Sanofi's Praluent And Amgen's Repatha Now Set For Battle In Europe, US
This article was originally published in The Pink Sheet Daily
Executive Summary
Praluent and Repatha are ready for a transatlantic showdown after regulatory approvals in Europe and US, but the jury remains out on which PCSK9 inhibitor will gain the upper hand.